SCHEMBL23934207

SCHEMBL23934207

CN1C(=O)c2c(N)ccc(N)c2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 3/20 0.50
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
USP2 O75604 2/20 0.47
ATM Q13315 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
ADORA2A P29274 5/20 0.41
CSNK1A1 P48729 2/20 0.41
CSNK1D P48730 2/20 0.41
CSNK1G1 Q9HCP0 2/20 0.41
FGR P09769 1/20 0.41
PIM1 P11309 1/20 0.41
MAOA P21397 1/20 0.41
DYRK1A Q13627 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CSNK2A3 Q8NEV1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2036747 0.80 MEN1 (0.58) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL13963497 0.76 CASP3 (0.42) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL20411709 0.72 KMT2A (0.65) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL23934280 0.70 MEN1 (0.41) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL7941648 0.69 MEN1 (0.40) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL17316947 0.69 MEN1 (0.40) THRBMEN1KMT2AUSP2ATM
SCHEMBL12019929 0.68 CASP3 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL21371643 0.68 CASP3 (0.38) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL13145748 0.68 CASP3 (0.38) MEN1KMT2AUSP2ATMKEAP1
SCHEMBL441644 0.68 MEN1 (0.47) MEN1KMT2AUSP2ATMKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 THRB 1499/4885MEN1 2490/4885KMT2A 2003/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 THRB 1499/4885MEN1 2490/4885KMT2A 2003/4885
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION BLVRB, TFPI, ETFB THRB 2894/4885MEN1 4178/4885KMT2A 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.